Organization (Industry)
Revision Skincare LLC (United States)
ClinicalTrials.gov lists Revision Skincare LLC (United States) as lead sponsor of 18 trials. It has 1 active development program.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 2.2 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Revision Skincare LLC (United States): 18 lead-sponsored trials and 1 legal-entity registration.
Disease areas (6)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Hyperpigmentation | 4 |
| Cutis Laxa | 3 |
| Alopecia | 1 |
| Cellulitis | 1 |
| Melanosis | 1 |
Showing 5 of 6 disease areas.
Trials by start year as sponsor or collaborator (8)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2025 | 1 |
| 2024 | 3 |
| 2023 | 2 |
| 2022 | 4 |
| 2021 | 3 |
| 2020 | 3 |
| 2019 | 1 |
| 2018 | 1 |
Recruitment duration, a model prediction: none of the 18 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (1)
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Sunscreen | Cutis Laxa | Not reported | 2 |
Journals published in (2)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Lasers in surgery and medicine | 1 |
| The Journal of clinical and aesthetic dermatology | 1 |
Organization relationships (2)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Dermico | Co sponsors trial with | 1 |
| SGS Stephens, Inc | Co sponsors trial with | 1 |
Latest dated events (18)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2025-08-11 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2024-10-21 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2024-10-07 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2024-02-19 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2023-10-03 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 18 events.
Biomarker capability evidence (6)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| PHLDA2 | Trial sponsor | Named in trial inclusion criteria |
| PHLDA2 | Trial sponsor | Named in trial exclusion criteria |
| PHLDA2 | Trial sponsor | Named in trial exclusion criteria |
| PHLDA2 | Trial sponsor | Mentioned in trial text |
| PHLDA2 | Trial sponsor | Mentioned in trial text |
Showing 5 of 6 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, approved assets, sponsor delivery record, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.